Log inStart free trialBook a demo
Book a demoLog inStart free trial
Media Database
>
Erik Swain

Erik Swain

Author at healio.com at Healio

Contact this person
Email address
e*****@*******.comGet email address
Influence score
32
Location
United States
Languages
  • English
Covering topics

    View more media outlets and journalists by signing up to Prowly

    View latest data and reach out all from one place
    Sign up for free

    Recent Articles

    healio.com

    CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes

    Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost 15.7% of their body weight at 68 weeks, according to topline data from the REDEFINE 2 trial. As Healio previously reported in December, CagriSema (Novo Nordisk) conferred a 22.7% weight loss at 68 weeks among adults with obesity and without diabetes in the REDEFINE 1 trial. In
    24 days ago
    healio.com

    ABMS denies independent medical board for cardiology

    The American Board of Medical Specialties denied approval of creation of an independent cardiology certification board championed by the American Board of Cardiovascular Medicine, according to a press release. Jeffrey Kuvin, MD, the Lorinda and Vincent de Roulet Professor of Medicine and chair of the department of cardiology at the Donald and Barbara Zucker School of Medicine at
    about 1 month ago
    healio.com

    FDA approves two new biosimilars of denosumab

    The FDA has approved two new biosimilars of denosumab to treat osteoporosis, increase bone mass, prevent skeletal-related events for people with multiple myeloma and other indications, Samsung Bioepis announced. Ospomyv (Samsung Bioepis) has been approved as a biosimilar referencing the osteoporosis therapy Prolia (Amgen). The biosimilar was approved to treat osteoporosis in postmenopausal women
    about 2 months ago
    healio.com

    Heart disease remains the No. 1 cause of death in women: Why?

    February is American Heart Month, a highlight of which is Wear Red Day, which aims to raise awareness about heart disease in women, on the first Friday of the month. Heart disease is the No. 1 cause of death in women. Many factors unique to women can raise heart disease risk, including pregnancy-related conditions and hormonal changes related to menopause. While efforts have been made to raise
    about 2 months ago
    healio.com

    Novel obesity drug induces up to 22% weight loss with no safety con...

    A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a significant weight reduction compared with placebo, according to top-line results from a phase 1b/2a trial. Amycretin (Novo Nordisk) is a once-weekly subcutaneous agent currently under development for the treatment of overweight or obesity and type 2 diabetes. There were
    2 months ago
    healio.com

    Race, sex disparities persist in weight-loss surgery

    Men were less likely than women to have weight-loss surgery, and that gap has widened over time, while Black patients were less likely than those of other races to have a procedure, and that gap has narrowed slightly, new data show. “Metabolic/bariatric surgery is a safe and very effective treatment of obesity,” Alexander Turchin, MD, MS, director of quality in diabetes at Brigham and
    3 months ago
    healio.com

    Novel drug confers weight loss of up to 20% at 1 year in phase 2 study

    Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to approximately 20% at 1 year in patients with overweight or obesity without a weight loss plateau, according to a presentation. Results from a double-blind, dose-ranging phase 2 study of maridebart cafraglutide (MariTide, Amgen) were presented at the World Congress on Insulin
    3 months ago
    healio.com

    Mifepristone reduces HbA1c in patients with hypercortisolism, type ...

    In patients with hypercortisolism and difficult-to-control type 2 diabetes, mifepristone lowered HbA1c at 24 weeks compared with placebo, researchers reported at World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.“I think [these results are] going to change how we manage these challenging patients,” Vivian A. Fonseca, MD, FRCP, professor of medicine, assistant
    3 months ago
    healio.com

    FDA clears novel at-home BP, pulse rate monitor

    Withings Health Solutions announced its novel cellular BP monitor received FDA clearance to measure BP and pulse rate in adults with arm circumferences of 22 cm to 42 cm or 40 cm to 52 cm. The device (BPM Pro 2) is designed to improve reliability of at-home BP measurements by continuously educating patients on how to take correct measurements, according to a company press release.
    3 months ago
    healio.com

    Zepbound bests Wegovy in head-to-head weight-loss trial

    Eli Lilly announced top-line results of the SURMOUNT-5 trial in which patients with overweight or obesity assigned tirzepatide lost more weight than those assigned semaglutide. SURMOUNT-5 was a phase 3b clinical trial comparing the GLP-1/GIP receptor agonist tirzepatide (Zepbound, Eli Lilly) with the GLP-1 receptor agonist semaglutide 2.4 mg (Wegovy, Novo Nordisk) for weight loss in patients with
    4 months ago
    healio.com

    Obicetrapib tied to sizable LDL lowering on top of other therapies ...

    CHICAGO — In patients with heterozygous familial hypercholesterolemia with high LDL despite being on optimal medical therapy, obicetrapib greatly lowered LDL levels compared with placebo, according to the results of the BROOKLYN trial. The phase 3 BROOKLYN trial, presented at the American Heart Association Scientific Sessions, included 354 patients diagnosed with heterozygous familial
    4 months ago